Get the Daily Brief
Latest Biotech News
Kyoto University Develops Protein Tool to Target Harmful Cells via Phagocytosis
Scientists at Kyoto University's iCeMS unveiled 'Crunch,' a synthetic protein that reprograms the body's phagocytes to selectively remove harmful living cells such as cancerous or overactive...
Novartis Invests $200M Upfront in Arrowhead’s RNAi Therapy Targeting Parkinson’s
Novartis forged a licensing agreement with Arrowhead Pharmaceuticals to develop ARO-SNCA, an RNA interference-based therapy targeting alpha-synuclein implicated in Parkinson's disease. The deal,...
Ionis Pharmaceuticals Expands Use of Oleazarsen After Positive Phase 3 for Hypertriglyceridemia
Ionis Pharmaceuticals announced favorable Phase 3 results for oleazarsen, its antisense oligonucleotide drug that significantly reduced triglyceride levels by up to 72% and decreased acute...
Eli Lilly’s Oral GLP-1 Orforglipron Shows Strong Weight Loss in Phase 3 Trial
Eli Lilly reported positive Phase 3 ATTAIN-2 trial results for orforglipron, an oral small molecule GLP-1 receptor agonist for obesity and type 2 diabetes. The highest dose yielded an average...
Medtech Partnerships Automate Nucleic Acid Quantification Workflows
Beckman Coulter Life Sciences and Hombrechtikon Systems Engineering (HSE) announced a strategic collaboration to automate nucleic acid quantification through integration of HSE photometer and...
Oxford Nanopore Revenues Rise 26% Driven by Clinical and Instrument Sales Growth
Oxford Nanopore Technologies reported a 26% year-over-year revenue increase for the first half of 2025, reaching £105.6 million ($141.3 million). Drivers include a 53% increase in instrument sales...
MedTech Giant Amgen Invests $600M to Expand California R&D Headquarters
Amgen announced a $600 million investment to expand its research and development site in Thousand Oaks, California. The state-of-the-art facility will focus on accelerating next-generation drug...
Moderna’s Spikevax LP.8.1 COVID-19 Vaccine Gains Approval in South Korea
South Korea’s Ministry of Food and Drug Safety approved Moderna’s updated Spikevax LP.8.1 vaccine targeting the LP.8.1 variant of SARS-CoV-2. This regulatory clearance follows the US FDA’s...
Bio-Thera's Stelara Biosimilar Receives European Commission Approval
Bio-Thera Solutions secured European Commission marketing authorization for Usymro (BAT-2206), a biosimilar to Janssen’s Stelara (ustekinumab). The EMA's positive opinion and subsequent approval...
Novartis Doubles Down on RNAi Parkinson’s Therapy with $2.2B Arrowhead Deal
Novartis has secured an exclusive licensing and collaboration agreement with Arrowhead Pharmaceuticals worth up to $2.2 billion, advancing Arrowhead’s RNA interference (RNAi) drug ARO-SNCA...
Ionis’ Tryngolza Clears Major Phase III Trials for Severe Hypertriglyceridemia
Ionis Pharmaceuticals’ antisense oligonucleotide drug, olezarsen (Tryngolza), demonstrated robust efficacy and safety in pivotal Phase III CORE and CORE2 trials for severe hypertriglyceridemia....
United Therapeutics’ Tyvaso Surprises with Phase III Idiopathic Pulmonary Fibrosis Win
United Therapeutics Corp. unveiled unexpectedly positive Phase III data for its nebulized treprostinil product, Tyvaso, in idiopathic pulmonary fibrosis (IPF), a notoriously difficult-to-treat...
Corsera Health Launches with $50M to Transform Cardiovascular Disease Prevention
Biotech veterans John Maraganore and Clive Meanwell have teamed to launch Corsera Health, backed by a $50 million initial funding round, focusing on prevention of cardiovascular disease through...
FDA Approvals and Regulatory Moves Shake Up US Biotech Landscape
The US Food and Drug Administration has recently cleared several significant approvals impacting biotech and healthcare. Highlights include FDA clearance of Geneseeq Technology’s GeneseeqPrime NGS...
Charm Therapeutics Raises $80M to Advance AI-Designed Menin Inhibitor into Clinic
Charm Therapeutics, a London-based biotech co-founded by Nobel laureate David Baker, completed an oversubscribed $80 million Series B to propel its AI-designed menin inhibitor into clinical...
Machine Learning and AI Drive Breakthroughs in Medical Diagnostics and Drug Design
Artificial intelligence and machine learning technologies have made significant inroads across medical diagnostics and therapeutic development. Notable achievements include the development of...
Revvity Opens In Vivo Imaging Center of Excellence to Accelerate Life Science Innovation
Revvity Inc. inaugurated its In Vivo Imaging Center of Excellence in Morrisville, North Carolina, consolidating expertise across software, hardware, and applied biology teams to accelerate...
Merck Advances Oral PCSK9 Program with Third Phase 3 Trial Success
Merck & Co. has achieved a third consecutive Phase 3 trial win for its oral PCSK9 inhibitor in hyperlipidemia, reinforcing its push towards broader regulatory discussions and market expansion. The...
Advances in Cancer Immunotherapy and Targeted Treatments Show Promise Across Cancers
Recent studies highlight progress in cancer immunotherapies and targeted therapies. UCSF researchers have developed a STAT3-targeted oligonucleotide showing efficacy in feline oral tumors,...
Novartis Renewed Bet on RNAi in Parkinson’s: $200M Upfront Arrowhead Deal
Novartis has renewed its pursuit of Parkinson’s disease treatments by licensing a preclinical RNA interference therapy from Arrowhead Pharmaceuticals, centered on silencing the alpha-synuclein...